Compare NVG & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NVG | HAE |
|---|---|---|
| Founded | 1999 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.9B |
| IPO Year | N/A | 1991 |
| Metric | NVG | HAE |
|---|---|---|
| Price | $13.35 | $57.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $86.00 |
| AVG Volume (30 Days) | 568.8K | ★ 1.1M |
| Earning Date | 01-01-0001 | 02-05-2026 |
| Dividend Yield | ★ 4.65% | N/A |
| EPS Growth | N/A | ★ 43.84 |
| EPS | N/A | ★ 3.65 |
| Revenue | N/A | ★ $1,318,275,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.86 |
| P/E Ratio | ★ N/A | $15.78 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.68 | $47.32 |
| 52 Week High | $12.21 | $87.32 |
| Indicator | NVG | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 67.13 | 23.44 |
| Support Level | $13.15 | $55.95 |
| Resistance Level | $13.59 | $60.50 |
| Average True Range (ATR) | 0.14 | 2.35 |
| MACD | 0.05 | -0.58 |
| Stochastic Oscillator | 66.98 | 15.70 |
Nuveen AMT-Free Municipal Credit Income Fund is a diversified, closed-end management investment company. Its objective is to provide current income exempt from regular federal income tax and federal alternative minimum tax applicable to individuals and enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the investment adviser believes are underrated or undervalued or represent undervalued municipal market sectors.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.